As of 2025-05-21, the Intrinsic Value of Natco Pharma Ltd (NATCOPHARM.NS) is 711.67 INR. This NATCOPHARM.NS valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 852.00 INR, the upside of Natco Pharma Ltd is -16.50%.
The range of the Intrinsic Value is 630.30 - 828.30 INR
Based on its market price of 852.00 INR and our intrinsic valuation, Natco Pharma Ltd (NATCOPHARM.NS) is overvalued by 16.50%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 630.30 - 828.30 | 711.67 | -16.5% |
| DCF (Growth 10y) | 604.96 - 748.10 | 664.80 | -22.0% |
| DCF (EBITDA 5y) | 1,628.36 - 1,963.75 | 1,795.96 | 110.8% |
| DCF (EBITDA 10y) | 1,232.94 - 1,565.86 | 1,391.78 | 63.4% |
| Fair Value | 2,603.30 - 2,603.30 | 2,603.30 | 205.55% |
| P/E | 2,940.80 - 4,042.39 | 3,450.32 | 305.0% |
| EV/EBITDA | 2,393.13 - 3,493.68 | 2,966.00 | 248.1% |
| EPV | 313.40 - 358.00 | 335.70 | -60.6% |
| DDM - Stable | 488.44 - 900.03 | 694.23 | -18.5% |
| DDM - Multi | 343.99 - 487.06 | 402.84 | -52.7% |
| Market Cap (mil) | 152,601.72 |
| Beta | 1.42 |
| Outstanding shares (mil) | 179.11 |
| Enterprise Value (mil) | 139,064.72 |
| Market risk premium | 8.31% |
| Cost of Equity | 14.67% |
| Cost of Debt | 6.73% |
| WACC | 14.45% |